Jaundice


Bilirubin is a by-product of heme metabolism. Heme is largely derived from the hemoglobin in senescent red blood cells and is oxidized in the spleen, liver, and other organs by two isoforms of the enzyme heme oxygenase, in the presence of nicotinamide adenine dinucleotide phosphate (NADPH) and molecular oxygen, to form biliverdin, carbon monoxide, and iron. Subsequently, biliverdin is converted into bilirubin by the phosphoprotein biliverdin reductase, which also uses NADPH as a cofactor. A visual representation of this pathway is shown in Fig. 23.1 . Bilirubin is a lipophilic molecule. To be excreted, bilirubin that is produced in extrahepatic organs is bound to albumin and transported to the liver. The liver takes up the bilirubin – albumin complex through an albumin receptor. Bilirubin, but not albumin, is transferred across the hepatocyte membrane and transported through the cytoplasm to the smooth endoplasmic reticulum bound primarily to ligandin or Y protein, a member of the glutathione S -transferase gene family of proteins. Within hepatocytes, bilirubin is converted to water-soluble derivatives, bilirubin monoglucuronide and bilirubin diglucuronide, by the enzyme uridine diphosphate-glucuronosyl transferase. These conjugated forms of bilirubin are secreted across the canalicular membrane into the bile via an energy-dependent process. Conjugated bilirubin is excreted in the bile into the intestine, where it is broken down by the gut microflora into urobilinogen and stercobilin.

Fig. 23.1
Pathway, Regulation, and Inhibitors of Heme Metabolism.
The first enzyme of the heme biosynthetic pathway, aminolevulinate ( ALA ) synthase ( ALAS ), is the rate-controlling enzyme of this pathway. Heme formation is subject to end-product regulation by negative feedback, but the exact point of metabolic control differs between hepatocytes and erythroid cells. In the liver, ALAS is regulated negatively by heme, the end product of the pathway. In contrast, in erythroid cells, ALAS is not under the same regulatory mechanism. Heme oxygenase (HO) is the rate-controlling enzyme of the heme degradation pathway. Succinylacetone (SA) is a potent inhibitor of ALA dehydratase activity. ZnPP9 is a potent inhibitor of HO activity.

(From Tatsuya I, Chiang G, Ronnett GV. The regulation of heme turnover and carbon monoxide biosynthesis in cultured primary rat olfactory receptor neurons. J Neurosci . 1996;16:5621–5628, Fig. 3.)

Total serum bilirubin consists of an unconjugated fraction and a conjugated fraction. The conjugated forms of bilirubin exist both freely in the serum and bound covalently to albumin. Conjugated bilirubin is water soluble and reacts directly to certain dyes added to the serum specimen. The unconjugated bilirubin does not react with the colorimetric reagents until a solvent is added. Accordingly, the conjugated and unconjugated forms of bilirubin are sometimes referred to as “direct” and “indirect” bilirubin. The sum of these two measurements is the “total” bilirubin. The normal total bilirubin concentration in adults is less than 18 μmol/L (1.0 mg/dL). Although any total bilirubin concentration higher than the upper limit of normal constitutes hyperbilirubinemia, jaundice (i.e., yellow discoloration of the sclerae, mucous membranes, and skin) is usually not clinically apparent unless the serum total bilirubin level is greater than 50 μmol/L (2.8 mg/dL). Unconjugated or indirect hyperbilirubinemia is present when the total serum bilirubin concentration is above the upper limit of normal and less than 15% of the total is in the direct or conjugated form.

Differential diagnosis

The multitude of diagnoses depicted in Box 23.1 divides the causes of hyperbilirubinemia into two large groups according to whether the predominant abnormality is an increase in the circulating concentration of unconjugated (indirect) bilirubin or an increase in the concentration of conjugated (direct) bilirubin. Although this classification scheme is useful under some circumstances, many of the diagnoses listed in Box 23.1 are extremely rare and highly unlikely to be encountered by the intensivist caring for critically ill (adult) patients. A more useful classification scheme is depicted in Box 23.2 . In this scheme, the causes of jaundice are grouped into three primary categories: extrahepatic obstruction to bile flow, increased bilirubin production, and impaired excretion secondary to hepatocellular necrosis and/or intrahepatic cholestasis and hepatitis. It is common for multiple mechanisms to be involved simultaneously.

BOX 23.1
Adapted from Bernstein MD. Hyperbilirubinemia. In Rakel RE, ed. Saunders Manual of Medical Practice. Philadelphia: Saunders; 1996:371–373, with permission.
Differential Diagnosis of Hyperbilirubinemia

  • A.

    Unconjugated hyperbilirubinemia

    • 1.

      Overproduction of bilirubin

      • a.

        Hemolysis, intravascular: disseminated intravascular coagulation

      • b.

        Hemolysis, extravascular

        • i.

          Hemoglobinopathies

        • ii.

          Enzyme deficiencies (e.g., glucose-6-phosphate dehydrogenase deficiency)

        • iii.

          Autoimmune hemolytic anemias

      • c.

        Ineffective erythropoiesis

      • d.

        Resorption of hematoma

      • e.

        Massive transfusion

    • 2.

      Hereditary unconjugated hyperbilirubinemia

      • a.

        Gilbert syndrome (autosomal dominant)

      • b.

        Crigler-Najjar syndrome type I (autosomal recessive)

      • c.

        Crigler-Najjar syndrome type II (autosomal dominant)

    • 3.

      Drugs

      • a.

        Chloramphenicol: neonatal hyperbilirubinemia

      • b.

        Vitamin K: neonatal hyperbilirubinemia

      • c.

        5-Beta-pregnane-3 alpha, 20-alpha-diol: cause of breast milk jaundice

  • B.

    Conjugated hyperbilirubinemia

    • 1.

      Inherited disorders

      • a.

        Dubin-Johnson syndrome (autosomal recessive)

      • b.

        Rotor syndrome (autosomal recessive)

    • 2.

      Hepatocellular diseases and intrahepatic causes

      • a.

        Viral hepatitis

      • b.

        Alcoholic hepatitis

      • c.

        Drug-induced hepatitis (e.g., because of isoniazid, nonsteroidal antiinflammatory drugs, and zidovudine)

      • d.

        Cirrhosis

      • e.

        Drug-induced cholestasis (e.g., because of prochlorperazine, haloperidol [Haldol], and estrogens)

      • f.

        Sepsis

      • g.

        Postoperative jaundice

      • h.

        Infiltrative liver disease: tumors, abscesses (pyogenic, amebic), tuberculosis, parasites (e.g., Toxoplasma ), Pneumocystis jirovecii pneumonia, Echinococcus

      • i.

        Primary biliary cirrhosis

      • j.

        Primary sclerosing cholangitis

    • 3.

      Extrahepatic causes

      • a.

        Gallstone disease

      • b.

        Pancreatitis-related stricture

      • c.

        Pancreatic head tumor

      • d.

        Cholangiocarcinoma

      • e.

        Primary sclerosing cholangitis

BOX 23.2
Classification for Acute Jaundice Associated With Critical Illness

  • I.

    Extrahepatic bile duct obstruction

    • A.

      Choledocholithiasis

    • B.

      Common bile duct stricture

    • C.

      Traumatic or iatrogenic common bile duct injury

    • D.

      Acute pancreatitis

    • E.

      Malignancy (e.g., ampullary carcinoma)

  • II.

    Increased bilirubin production

    • A.

      Massive transfusion

    • B.

      Resorption of blood collections (e.g., hematomas, hemoperitoneum)

    • C.

      Acute hemolysis

      • 1.

        Disseminated intravascular coagulation

      • 2.

        Immune-mediated

  • III.

    Impaired excretion because of hepatocellular dysfunction, hepatitis, or intrahepatic cholestasis

    • A.

      Drug- or alcohol-induced hepatitis

    • B.

      Drug-induced intrahepatic cholestasis

    • C.

      Drug-induced hepatocellular necrosis

    • D.

      Gilbert syndrome

    • E.

      Sepsis and other causes of systemic inflammation

    • F.

      Total parenteral nutrition

    • G.

      Viral hepatitis

Hyperbilirubinemia occurs frequently in critically ill patients and is an independent risk factor for an unfavorable outcome. , In a retrospective study of adult patients admitted to an intensive care unit (ICU) with severe sepsis or septic shock, the mortality rate was 12%, 24%, and 42% for individuals with a peak serum bilirubin concentration during the first 72 hours that was ≤1, 1.1–2, or >2 mg/dL, respectively. In another retrospective study, hyperbilirubinemia was a significant risk factor for the development of acute respiratory distress syndrome (ARDS) among patients admitted to an ICU with sepsis. In one widely cited study, hyperbilirubinemia occurred in 217 of 2857 trauma patients who had an Injury Severity Score greater than 14 and survived for longer than 48 hours after admission to the hospital. In this study, hyperbilirubinemia was significantly associated with an increased length of stay in the ICU and death. Hyperbilirubinemia is also common in ICU patients who are recovering from cardiac surgery. , In this category of ICU patients, risk factors for the development of hyperbilirubinemia include prolonged cardiopulmonary bypass time, prolonged aortic cross-clamp time, and use of an intraaortic balloon pump.

Determining the cause of new-onset hyperbilirubinemia is important when managing ICU patients because some problems can be corrected. Exclusion of a mechanical cause for jaundice (e.g., obstruction of the common bile duct because of choledocholithiasis or stricture) assumes the highest priority because failure to correct this type of problem in a timely fashion can lead to serious morbidity or even mortality. Fig. 23.2 shows an approach to handling new-onset hyperbilirubinemia in an adult patient. Hyperbilirubinemia is multifactorial, and although laboratory values evaluating the production and excretion of bilirubin can guide the workup, a liver biopsy or cholangiography is necessary when no other diagnosis can be confirmed.

Fig. 23.2, Algorithm for a Systematic Approach to the Adult Patient with Jaundice.

Iatrogenic injuries to the common bile duct are fortunately quite rare. Damage to the biliary tree, stricture of biliary anastomoses, and retained stones after cholecystectomy or common bile duct exploration present as hyperbilirubinemia and elevated circulating levels of alkaline phosphatase or gamma-glutamyltransferase. Most often the diagnosis is made by detecting the dilation of intrahepatic and extrahepatic bile ducts using ultrasonography.

By exceeding the capacity of the liver to conjugate and excrete bilirubin into the bile, hemolysis can result in jaundice. However, the liver can excrete approximately 300 mg/day of bilirubin, and therefore clinically significant hyperbilirubinemia is only apparent if the rate of hemolysis (i.e., the number of red blood cells lysed per unit time) is fairly rapid. Approximately 10% of the erythrocytes in an appropriately cross-matched unit of packed red blood cells undergo rapid hemolysis, yielding about 250 mg of bilirubin. Accordingly, transfusion of a single unit of packed red blood cells is not likely to increase the total serum bilirubin concentration. However, transfusion of multiple units of blood over a short period almost inevitably leads to some degree of hyperbilirubinemia, particularly if hepatic functionality is already impaired. Other common causes of acute hemolysis in ICU patients include sickle cell disease, immune-mediated hemolytic anemia, and disseminated intravascular coagulation.

Any condition that leads to extensive hepatocellular damage will increase the circulating total bilirubin concentration. Conditions in this category that are commonly encountered in ICU patients include viral hepatitis, “shock liver,” alcoholic hepatitis, and hepatocellular injury induced by drugs, especially acetaminophen. In most forms of jaundice resulting from hepatic inflammation or hepatocellular damage, circulating levels of transaminases are elevated to a greater extent than the total bilirubin concentration. Making a diagnosis of acetaminophen overdose early is extremely important because specific therapy using N -acetylcysteine can be lifesaving.

Efforts to understand the pathophysiologic mechanisms responsible for cholestatic jaundice resulting from sepsis have largely focused on lipopolysaccharide (LPS)-induced alterations in the function and expression of various bile acid transporters. Nevertheless, another factor that likely contributes to the development of intrahepatic cholestasis is the back-leakage of bile from the canalicular spaces into the sinusoids.

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here